Calliditas (CALT): Net earnings per share (EPS TTM)

The rolling annual EPS chart demonstrates the financial dynamics of Calliditas Therapeutics (CALT), where the current level is approximately -1.69. The implementation of strict eco-standards and safe laboratory protocols minimizes the company's risks. Business development relies on patent licenses and strategic alliances, while dependence on a single drug is offset by a merger with a major medical holding.

Calliditas Therapeutics revenues depend directly on the approval of insurance reimbursements and the scaling of sales for its rare kidney disease therapy. This indicator calculates the net profit allocated per share annually, separating operational efficiency from the market price. Growth in this metric confirms the successful commercialization of the drugs. By analyzing the current trailing 12-month EPS, an investor can identify if the asset is overvalued, which helps avoid purchasing overheated securities.